Skip to main content
TipRanks
Go Ultimate75% OFF

Roche Holding Ltd CAD Hedged CIBC CDR (ROG) Q2 2026 Earnings Report

2 Followers

TSE:ROG Q2 2026 EPS Results

Actual EPS
CAD 0.71
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
CAD 0.71

TSE:ROG Q2 2026 Revenue Results

Actual Revenue
CAD 53.17B
Expected Revenue
―
Beat/Miss
―
YoY Revenue Growth
+5.13%

Earnings Announcement Details

Quarter
Q2 2026
Date
07/23/2026
Time
Before Open
Conference Call
Thursday, July 23, 2026
TSE:ROG Upcoming Earnings

Roche Holding Ltd CAD Hedged CIBC CDR's next earnings date is estimated for January 28, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Jul 23, 2026|% Change Since:22.44%|
Earnings Call Sentiment|Positive

The call conveyed strong confidence in Roche's operating performance, with broad sales growth, 10% core operating profit growth, expanding margins, strong cash flow, significant regulatory progress, and extensive late-stage pipeline momentum. The company also confirmed its full-year outlook and highlighted multiple growth platforms across Pharma and Diagnostics. Offsetting issues included foreign exchange pressure, China's pricing reform, a weak respiratory season, loss-of-exclusivity effects, competitive pressure on selected products, and a higher expected second-half tax rate. Overall, the positive financial, operational, and pipeline developments significantly outweighed the stated challenges.

Company Guidance

Roche confirmed mid-single-digit sales growth, currently growing 6%, high single-digit core EPS growth, growing 9%, and that it will further increase dividends in Swiss francs; the LOE impact is roughly CHF 600 million now expected for 2026, “a little lower” was possible, and everything else was confirmed as at the beginning of 2026. Diagnostics’ 2026 ambition is to grow sales at mid-single digits and keep its margin broadly stable at constant exchange versus 14.4% from full year 2025, with an ambition to return to mid- to high single-digit sales growth in 2027; brand guidance included flat growth for Alecensa through the end of the year, low single-digit growth for Tecentriq, mid-single digit growth for Hemlibra, the lower end of the high single digit to low double-digit range for the Ocrevus franchise, around 20% growth for Xolair, and low double-digit growth globally for Vabysmo, with U.S. growth in the low single to mid-single-digit range.

  • Strong Group Financial PerformanceRoche reported sales growth of 6% at constant exchange rates, core operating profit growth of 10%, core operating margin expansion of 1.7 percentage points, core EPS growth of 9%, operating free cash flow growth of 21%, and free cash flow growth of 58%. In Swiss francs, sales declined 2%, operating free cash flow increased 2%, and free cash flow increased 26%; in U.S. dollars, sales grew 8%.
  • Positive Full-Year Outlook ConfirmedRoche confirmed its outlook for mid-single-digit sales growth, high single-digit core EPS growth, and a further increase in dividends in Swiss francs. The company also confirmed its other 2026 guidance, including an expected loss of roughly CHF 600 million from loss of exclusivity.
  • Growth Across Both DivisionsPharma sales grew 6% at constant exchange rates to CHF 23.6 billion, while Diagnostics sales grew 3% at constant exchange rates to CHF 6.7 billion. Pharma volumes increased 9%, Diagnostics volumes increased 5%, and all Pharma regions delivered growth, with international markets and Japan growing at double-digit rates.
  • Core Operating Margin Expansion and Cost DisciplineCore operating margin increased by 1.7 percentage points at constant exchange rates, driven by both divisions. Pharma margin increased by 2 percentage points and Diagnostics margin increased by 0.6 percentage points. R&D expenses increased 1% for the Group, SG&A increased 3%, and cost of sales increased 5% while overall volume increased 8%.
  • Improved Cash Flow GenerationOperating free cash flow increased 21% at constant exchange rates, supported by higher operating profit and cash adjustments, while investments in property, plant and equipment were flat and investments in intangible assets were lower than the prior year. Free cash flow increased 58%, although the company described this as partly a timing effect.
  • Significant Regulatory ProgressRoche reported five U.S. FDA priority reviews during the year for giradestrant, inavolisib or the related breast cancer program, Tecentriq, Gazyva in lupus nephritis, and Gazyva in membranous nephropathy. The company also reported multiple regulatory filings, including Gazyva filings in membranous nephropathy and progress toward additional thyroid eye disease and oncology filings.
  • Strong Phase III Pipeline SuccessRoche reported two positive Phase III results in the second quarter and an 80% Phase III success rate year-to-date, which management described as significantly above the industry average. The company expects substantial news flow in the second half of 2026 and additional potentially significant readouts during 2027, 2028, and 2029.
  • Pipeline Value and R&D Efficiency IncreasedManagement stated that the value of the pipeline has increased 93% versus the end of 2022 and is at an all-time high. Roche reported reallocating approximately CHF 1.3 billion through R&D efficiencies, including savings from CRO contract renegotiations and improvements in the profitability of its Genentech-related operations.
  • Positive Oncology DevelopmentsThe Phase III KRASCENDO-1 study of divarasib in second-line or later KRAS G12C-positive non-small cell lung cancer showed superiority in progression-free survival and overall survival versus approved KRAS G12C inhibitors, with overall-survival statistical significance reached at the interim analysis. Roche also reported positive first-line data from KRASCENDO-170 and continued development of a broad RAS-targeted program.
  • Phesgo Conversion and Oncology Pipeline ProgressPhesgo's global conversion rate reached 54%, with Roche targeting at least 60% conversion at peak. The HER2 franchise is expected to peak at around CHF 9 billion in 2026 constant exchange rates, followed by a steady decline and a solid tail of around CHF 4 billion through the end of the decade. Polivy continued to gain first-line DLBCL market share, with more than 120,000 patients treated globally in that setting, up from 95,000 in Q1.
  • Hematology Franchise GrowthThe hematology franchise grew 14% at constant exchange rates to CHF 4.6 billion. Hemlibra delivered double-digit growth in the first half, prompting Roche to raise its full-year growth outlook to mid-single digit from previously low single digit, while management continued to highlight strong adoption among non-inhibitor patients and older adults.
  • Neurology Franchise and Ocrevus Subcutaneous AdoptionThe neurology franchise grew 9% at constant exchange rates to CHF 5 billion. Approximately 44,000 patients were using subcutaneous Ocrevus, up from roughly 24,000 in Q1. Roche continues to expect Ocrevus franchise peak sales of CHF 9 billion by 2029, including CHF 2 billion of incremental sales from the subcutaneous formulation.
  • Immunology Launch ProgressThe immunology franchise grew 8% at constant exchange rates to CHF 3.3 billion. More than 130,000 patients have been treated with Xolair for food allergy since launch, and Roche continues to expect around 20% growth for Xolair in 2026. Gazyva showed strong early uptake in lupus nephritis, with patient shares approaching 10% in the United States, Germany, and the United Kingdom, and Roche cited an opportunity of up to CHF 2 billion across immunology kidney indications.
  • Gazyva Membranous Nephropathy Results and FilingsIn the Phase III MAGEC study, Gazyva demonstrated superiority over tacrolimus on complete response in membranous nephropathy. Roche achieved U.S. and EU filings, received FDA Breakthrough Therapy designation and priority review, and received a November 15 PDUFA date for the indication.
  • Ophthalmology and Vabysmo MomentumOphthalmology sales grew 6% to CHF 2.1 billion. Vabysmo continued to expand global market share, with more than 60% of U.S. patient starts being treatment-naive. Vabysmo sales grew 8% in the first half while global volume increased 30%, and Roche expects low double-digit global growth, driven by markets outside the United States.
  • Obesity Pipeline ProgressRoche reported positive Phase II data for petrelintide, including double-digit weight loss and placebo-like tolerability, and made the decision to initiate Phase III development in the second half of 2026. For enicepatide, 48% of patients at the highest 24 mg dose achieved more than 20% weight loss, 38% achieved more than 25% weight loss, and 26% achieved more than 30% weight loss at 48 weeks. Roche is also initiating a Phase II combination study of enicepatide and petrelintide.
  • Diagnostics Growth Excluding ChinaDiagnostics sales grew 3% at constant exchange rates to CHF 6.7 billion, or 6% excluding the impact of China's health care pricing reform. Core Lab grew 4%, or 8% excluding China, Molecular Lab grew 3% with transplant testing up 18%, Pathology Lab grew 11%, advanced staining grew 7%, and companion diagnostics grew 24%.
  • Diagnostics Regional and Business PerformanceDiagnostics sales grew 8% in North America, 3% in EMEA, and 10% in Latin America. Blood glucose monitoring grew 3% following competitive wins, while the pathology business delivered strong growth. Roche stated an ambition to return Diagnostics to mid- to high-single-digit sales growth in 2027.
  • New Diagnostics Launches and TechnologyRoche launched the AXELIOS 1 sequencing solution on June 29 and reported capabilities including 1.8 terabases of SBX Duplex output in four hours, equivalent to approximately 16 whole human genomes, with a Q score of 38, or approximately 99.98% accuracy. The Simplex mode can generate 40 billion reads in a four-hour run, with average read lengths of 175 base pairs and reads of up to 1,500 bases.
  • PathAI and Oncology Diagnostics ExpansionRoche signed a definitive merger agreement with PathAI to combine AI-powered digital pathology image management and algorithms with Ventana staining and companion-diagnostics capabilities. Management stated that the combination will support cancer diagnosis, clinical decision support, clinical trials, and new biomarker development.
  • New Alzheimer's and Tuberculosis TestsRoche received a CE mark for its Elecsys pTau217 Alzheimer's disease blood test, described as a minimally invasive alternative to imaging and other diagnostic methods. Roche also received a CE mark for its Elecsys interferon gamma release assay for latent tuberculosis, designed for automated high-throughput testing and supported by the company's broad installed base of immunoassay analyzers.
  • Diagnostics Launch ExecutionRoche reported that it had achieved seven of the 11 Diagnostics launches on its key launch list by the end of the first half of 2026.
  • Disciplined Business Development and External InnovationManagement emphasized disciplined business development and stated that Roche was often not the highest bidder when winning deals. Recent activities included PathAI, Saga Diagnostics, and a partnership with Nurix or Nex Therapeutics around a BTK degrader, which Roche plans to develop across hematology and potentially immunology and neurology.

TSE:ROG Earnings History

TSE:ROG earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Jan 28, 20272026 (Q4)―-0.56――
Jul 23, 20262026 (Q2)―0.710.71-0.56% (-0.00)
Jan 29, 20262025 (Q4)―0.56――
Jul 24, 20252025 (Q2)―0.71――
Jan 30, 20252024 (Q4)―0.190.39-51.79% (-0.20)
Jul 25, 20242024 (Q2)―0.560.62-9.09% (-0.06)
Feb 01, 20242023 (Q4)―0.390.3124.20% (+0.08)
Jul 27, 20232023 (Q2)―0.62――
Feb 02, 20232022 (Q4)―0.310.46-32.33% (-0.15)
Jul 21, 20222022 (Q2)―-――

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed